Vitamin K2 in the MK-7 form has drawn growing interest in cardiovascular research for a specific reason: it activates matrix Gla-protein, a protein that helps keep calcium out of arterial walls rather than bone, where it belongs. A trio of clinical trials — most notably the AVADEC (Aortic Valve Decalcification) study, published in the Journal of the American College of Cardiology — has tested this mechanism directly against coronary artery calcification and arterial stiffness, real markers tied to cardiovascular risk.
The AVADEC Trial: An Honest Look at a Subgroup Finding
AVADEC investigated daily vitamin K2 MK-7 (720 µg/day) plus vitamin D (25 µg/day) supplementation over two years, tracking coronary artery calcification (CAC) progression — a well-established marker strongly associated with heart disease risk. It’s worth being direct about what the trial found: across the total study group, there was no significant effect on CAC score.
Where the Effect Did Show Up
In a subgroup analysis of participants at high risk of calcification (CAC score ≥400, no prior ischemic heart disease), two years of K2 MK-7 and vitamin D significantly slowed CAC progression compared to placebo. Statin users in the trial also showed a significant slowdown in CAC progression with the K2/D intervention. Separately, the number of serious cardiovascular events — heart attack, coronary revascularization, and all-cause death — was lower in the supplemented group than placebo, though this was a secondary observation, not the trial’s primary powered endpoint.
Two Supporting Trials on Arterial Stiffness
A separate trial in chronic hemodialysis patients with diabetes — a population with elevated cardiovascular risk — found that 375 µg/day of K2 MK-7 for 24 weeks meaningfully slowed the rate of arterial stiffness progression compared to control. Another trial in vitamin K-deficient kidney transplant recipients found that 360 µg/day of K2 MK-7 for 12 weeks supported healthier progression of arterial elasticity.
Why These Findings Aren’t a Blanket Claim
The honest reading of AVADEC is that vitamin K2 MK-7 plus vitamin D did not show a general population-wide effect on coronary calcification — the benefit was specific to a defined high-risk subgroup and to statin users. That’s a real, clinically meaningful signal for those particular populations, but it’s a narrower claim than “vitamin K2 prevents arterial calcification” in general, and subgroup findings in clinical trials — even genuine ones — typically call for confirmation in a dedicated follow-up trial before being treated as established.
The Bottom Line
Across three separate clinical studies, vitamin K2 MK-7 (often paired with vitamin D) shows a consistent, mechanistically coherent signal on vascular calcification and arterial stiffness — strongest in populations already at elevated cardiovascular risk (high baseline CAC scores, statin users, dialysis patients, transplant recipients with vitamin K deficiency). The principal investigator of the AVADEC trial himself frames this as “promising insights” that fill a knowledge gap, not a settled, universal recommendation — an appropriately measured way to describe where this research currently stands.
References
[1] Diederichsen, A. et al. AVADEC (Aortic Valve Decalcification) trial. J. Am. Coll. Cardiol., as summarized by Balchem Corporation, “New Peer-Reviewed Research Highlights Promising Potential of Vitamin K2 MK-7 for Heart Health,” 1 February 2024.
